Company intelligence / Profile preview

VelaBio

Cambridge, Massachusetts, USA

Ownership: Private
Employees: ~20
Development stage: Other

Overview

Vela Biotherapeutics is a clinical-stage biotechnology company dedicated to developing transformative medicines for patients with severe mental illness. The company's lead candidate, VELA-001, is a potent and selective small molecule antagonist of the vasopressin 1a (V1a) receptor, currently being evaluated in a Phase 2 clinical trial for Borderline Personality Disorder (BPD). VelaBio utilizes a precision medicine approach to psychiatry, targeting specific neurobiological pathways to address conditions with significant unmet medical needs. Founded by Atlas Venture, the company is led by an experienced team of drug developers and neuroscientists based in Cambridge, Massachusetts.

Therapeutic areas: Psychiatry
Modalities: Small molecule
Industry: Biotech

Partnerships

Azevan Pharmaceuticals

Beyond the preview

Go deeper on VelaBio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VelaBio.

Explore the full profile